UNSPSC 51382906: Glucosamine sulfate

This classification denotes a nutritional supplement with the molecular formula 2C6H13NO5.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FW7WLR731, chemically known as d-glucose, 2-amino-2-deoxy-, sulfate (salt) but more generally known as glucosamine sulfate, which bears US NIH Compound Identifier 115046. European Medicines Agency schedules Glucosamine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02356MIG.

UNSPSC 51382906 Glucosamine sulfate, a Commodity code, shows minimal alignment between its nominal scope and recent state and local procurement activity. The code's three most recent opportunities — a Seminole County naloxone and drug deactivation systems bid, a Texas HHS direct-to-manufacturer prescription program RFI, and a Minnesota multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products — center on pharmaceutical procurement, opioid-response supplies, and pharmacy benefit management rather than glucosamine sulfate specifically. State and local governments use this code family to acquire a broad range of pharmaceutical products, OTC medications, and health-system supplies through both individual jurisdiction IFBs and cooperative purchasing vehicles that serve multi-state consortia.

Issuing bodies soliciting under this code span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participants). The MMCAP cooperative vehicle appears to be a repeat mechanism for state and local pharmaceutical procurement. Recent geographic activity centers on Florida, Texas, and Minnesota, with the MMCAP contract reaching participating jurisdictions across multiple states. Seminole County's IFB60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathered vendor capabilities for direct pharmaceutical manufacturer relationships; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 sought generic multi-source pharmaceutical and OTC product manufacturers with a March 26, 2026 response date, targeting contract effectiveness July 1, 2026. The code shows little recent activity specifically tied to glucosamine sulfate procurement.